Document is current
Any future updates will be listed below
-
Authors
Ianiro, Gianluca https://orcid.org/0000-0002-8318-0515
Rossi, Ernesto https://orcid.org/0000-0002-6442-1707
Thomas, Andrew M. https://orcid.org/0000-0001-5789-3354
Schinzari, Giovanni
Masucci, Luca https://orcid.org/0000-0002-8358-6726
Quaranta, Gianluca
Settanni, Carlo Romano
Lopetuso, Loris Riccardo
Armanini, Federica
Blanco-Miguez, Aitor
Asnicar, Francesco
Consolandi, Clarissa
Iacovelli, Roberto https://orcid.org/0000-0002-1750-2117
Sanguinetti, Maurizio https://orcid.org/0000-0002-9780-7059
Tortora, Giampaolo
Gasbarrini, Antonio
Segata, Nicola https://orcid.org/0000-0002-1583-5794
Cammarota, Giovanni https://orcid.org/0000-0002-3626-6148
- License Information
-
More Information
Article History
Received: 28 May 2020
Accepted: 5 August 2020
First Online: 28 August 2020
Competing interests
: A.G. reports personal fees for consultancy for Eisai S.r.l., 3PSolutions, Real Time Meeting, Fondazione Istituto Danone, Sinergie S.r.l. Board MRGE and Sanofi S.p.A, personal fees for acting as a speaker for Takeda S.p.A, AbbVie and Sandoz S.p.A and personal fees for acting on advisory boards for VSL3 and Eisai. G.C. has received personal fees for acting as advisor for Ferring Therapeutics. G.I. has received personal fees for acting as speaker for Biocodex, Danone, Metagenics, and for acting as consultant/advisor for Ferring Therapeutics, Giuliani, Metagenics. None of the other authors has any competing interest to disclose.
